Showing results (2211-2220 of 2,317) with videos related to
Sort By:
Pageof 232
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.Thoracic Cancer|September 26, 2018
Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional studyYing Cheng, Yan Wang, Jun Zhao, et al.The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2021
A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II StudyQing Zhou, Lin Wu, Pei Hu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b TrialShen Zhao, Huaqiang Zhou, Nong Yang, et al.The European Respiratory Journal|January 22, 2026
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertensionChao Liu, Bao-Chen Qiu, Shuang-Ping Li, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.Pageof 232